Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 266

1.

Summit proceedings: Biomedical countermeasure development for emerging vector-borne viral diseases.

Blackman MA, Marchionni MA, Gilly J, Hepburn M, Innis BL, Barrett ADT, Kester KE, Mascola JR, Cummings JF, Monath TP, Cassetti MC, Kim JH, Saville M, Thomas SJ.

Vaccine. 2019 Sep 6. pii: S0264-410X(19)31137-5. doi: 10.1016/j.vaccine.2019.08.061. [Epub ahead of print]

PMID:
31500964
2.

Twenty Years of Progress Toward West Nile Virus Vaccine Development.

Kaiser JA, Barrett ADT.

Viruses. 2019 Sep 5;11(9). pii: E823. doi: 10.3390/v11090823. Review.

3.

Attenuation of Zika Virus by Passage in Human HeLa Cells.

Li L, Collins ND, Widen SG, Davis EH, Kaiser JA, White MM, Greenberg MB, Barrett ADT, Bourne N, Sarathy VV.

Vaccines (Basel). 2019 Aug 20;7(3). pii: E93. doi: 10.3390/vaccines7030093.

4.

Terrestrial Bird Migration and West Nile Virus Circulation, United States.

Swetnam D, Widen SG, Wood TG, Reyna M, Wilkerson L, Debboun M, Symonds DA, Mead DG, Beaty BJ, Guzman H, Tesh RB, Barrett ADT.

Emerg Infect Dis. 2018 Dec;24(12):2184-2194. doi: 10.3201/eid2412.180382.

5.

Structural and Nonstructural Genes Contribute to the Genetic Diversity of RNA Viruses.

Collins ND, Beck AS, Widen SG, Wood TG, Higgs S, Barrett ADT.

MBio. 2018 Oct 30;9(5). pii: e01871-18. doi: 10.1128/mBio.01871-18.

6.

West Nile in Europe: an increasing public health problem.

Barrett ADT.

J Travel Med. 2018 Jan 1;25(1). doi: 10.1093/jtm/tay096. No abstract available.

PMID:
30289526
7.

Analysis By Deep Sequencing of Discontinued Neurotropic Yellow Fever Vaccine Strains.

Beck AS, Wood TG, Widen SG, Thompson JK, Barrett ADT.

Sci Rep. 2018 Sep 7;8(1):13408. doi: 10.1038/s41598-018-31085-2.

8.

The reemergence of yellow fever.

Barrett ADT.

Science. 2018 Aug 31;361(6405):847-848. doi: 10.1126/science.aau8225. Epub 2018 Aug 23. No abstract available.

PMID:
30139914
9.

Developing Zika vaccines: the lessons for disease X.

Barrett ADT.

Genome Med. 2018 Jun 26;10(1):47. doi: 10.1186/s13073-018-0561-2.

10.

Current status of Zika vaccine development: Zika vaccines advance into clinical evaluation.

Barrett ADT.

NPJ Vaccines. 2018 Jun 11;3:24. doi: 10.1038/s41541-018-0061-9. eCollection 2018. Review.

11.

Spectrum of activity testing for therapeutics against all four dengue virus serotypes in AG129 mouse models: Proof-of-concept studies with the adenosine nucleoside inhibitor NITD-008.

Milligan GN, White M, Zavala D, Pyles RB, Sarathy VV, Barrett ADT, Bourne N.

Antiviral Res. 2018 Jun;154:104-109. doi: 10.1016/j.antiviral.2018.04.012. Epub 2018 Apr 14.

12.

Current status of Severe Fever with Thrombocytopenia Syndrome vaccine development.

Reece LM, Beasley DW, Milligan GN, Sarathy VV, Barrett AD.

Curr Opin Virol. 2018 Apr;29:72-78. doi: 10.1016/j.coviro.2018.03.005. Epub 2018 Apr 9. Review.

PMID:
29642053
13.

Baseline mapping of Lassa fever virology, epidemiology and vaccine research and development.

Hallam HJ, Hallam S, Rodriguez SE, Barrett ADT, Beasley DWC, Chua A, Ksiazek TG, Milligan GN, Sathiyamoorthy V, Reece LM.

NPJ Vaccines. 2018 Mar 20;3:11. doi: 10.1038/s41541-018-0049-5. eCollection 2018. Review.

14.

Characterization of a murine model of non-lethal, symptomatic dengue virus infection.

Sarathy VV, White M, Li L, Kaiser JA, Campbell GA, Milligan GN, Bourne N, Barrett ADT.

Sci Rep. 2018 Mar 20;8(1):4900. doi: 10.1038/s41598-018-22618-w.

15.

Clinical development and regulatory points for consideration for second-generation live attenuated dengue vaccines.

Vannice KS, Wilder-Smith A, Barrett ADT, Carrijo K, Cavaleri M, de Silva A, Durbin AP, Endy T, Harris E, Innis BL, Katzelnick LC, Smith PG, Sun W, Thomas SJ, Hombach J.

Vaccine. 2018 Jun 7;36(24):3411-3417. doi: 10.1016/j.vaccine.2018.02.062. Epub 2018 Mar 7.

16.

Zika, dengue and yellow fever viruses induce differential anti-viral immune responses in human monocytic and first trimester trophoblast cells.

Luo H, Winkelmann ER, Fernandez-Salas I, Li L, Mayer SV, Danis-Lozano R, Sanchez-Casas RM, Vasilakis N, Tesh R, Barrett AD, Weaver SC, Wang T.

Antiviral Res. 2018 Mar;151:55-62. doi: 10.1016/j.antiviral.2018.01.003. Epub 2018 Jan 10.

17.

Zika vaccine candidates progress through nonclinical development and enter clinical trials.

Barrett ADT.

NPJ Vaccines. 2016 Nov 10;1:16023. doi: 10.1038/npjvaccines.2016.23. eCollection 2016. No abstract available.

18.

Active evolution of memory B-cells specific to viral gH/gL/pUL128/130/131 pentameric complex in healthy subjects with silent human cytomegalovirus infection.

Xia L, Tang A, Meng W, Freed DC, He L, Wang D, Li F, Li L, Xiong W, Gui X, Schultz RD, Chen H, He X, Swoyer R, Ha S, Liu Y, Morris CD, Zhou Y, Wang IM, Zhao Q, Luo W, Xia N, Espeseth AS, Hazuda DJ, Rupp RE, Barrett AD, Zhang N, Zhu J, Fu TM, An Z.

Oncotarget. 2017 Jun 3;8(43):73654-73669. doi: 10.18632/oncotarget.18359. eCollection 2017 Sep 26.

19.

A lethal model of disseminated dengue virus type 1 infection in AG129 mice.

Milligan GN, Sarathy VV, White MM, Greenberg MB, Campbell GA, Pyles RB, Barrett ADT, Bourne N.

J Gen Virol. 2017 Oct;98(10):2507-2519. doi: 10.1099/jgv.0.000923. Epub 2017 Sep 27.

20.

A single-dose live-attenuated vaccine prevents Zika virus pregnancy transmission and testis damage.

Shan C, Muruato AE, Jagger BW, Richner J, Nunes BTD, Medeiros DBA, Xie X, Nunes JGC, Morabito KM, Kong WP, Pierson TC, Barrett AD, Weaver SC, Rossi SL, Vasconcelos PFC, Graham BS, Diamond MS, Shi PY.

Nat Commun. 2017 Sep 22;8(1):676. doi: 10.1038/s41467-017-00737-8.

21.

Virulence determinants of West Nile virus: how can these be used for vaccine design?

Kaiser JA, Wang T, Barrett AD.

Future Virol. 2017 May;12(5):283-295. doi: 10.2217/fvl-2016-0141. Epub 2017 Apr 28. Review.

22.

Genomic Characterization of Crimean-Congo Hemorrhagic Fever Virus in Hyalomma Tick from Spain, 2014.

Cajimat MNB, Rodriguez SE, Schuster IUE, Swetnam DM, Ksiazek TG, Habela MA, Negredo AI, Estrada-Peña A, Barrett ADT, Bente DA.

Vector Borne Zoonotic Dis. 2017 Oct;17(10):714-719. doi: 10.1089/vbz.2017.2190. Epub 2017 Aug 24.

PMID:
28836897
23.

p38MAPK plays a critical role in induction of a pro-inflammatory phenotype of retinal Müller cells following Zika virus infection.

Zhu S, Luo H, Liu H, Ha Y, Mays ER, Lawrence RE, Winkelmann E, Barrett AD, Smith SB, Wang M, Wang T, Zhang W.

Antiviral Res. 2017 Sep;145:70-81. doi: 10.1016/j.antiviral.2017.07.012. Epub 2017 Jul 21.

24.

Vaccine Mediated Protection Against Zika Virus-Induced Congenital Disease.

Richner JM, Jagger BW, Shan C, Fontes CR, Dowd KA, Cao B, Himansu S, Caine EA, Nunes BTD, Medeiros DBA, Muruato AE, Foreman BM, Luo H, Wang T, Barrett AD, Weaver SC, Vasconcelos PFC, Rossi SL, Ciaramella G, Mysorekar IU, Pierson TC, Shi PY, Diamond MS.

Cell. 2017 Jul 13;170(2):273-283.e12. doi: 10.1016/j.cell.2017.06.040.

25.

A DENV-2-type-specific monoclonal antibody binds to the DENV-complex-reactive antigenic site on envelope protein domain 3.

Sarathy VV, Pitcher TJ, Gromowski GD, Roehrig JT, Barrett ADT.

J Gen Virol. 2017 Jun;98(6):1299-1304. doi: 10.1099/jgv.0.000785. Epub 2017 Jun 20.

PMID:
28631593
26.

A live-attenuated Zika virus vaccine candidate induces sterilizing immunity in mouse models.

Shan C, Muruato AE, Nunes BTD, Luo H, Xie X, Medeiros DBA, Wakamiya M, Tesh RB, Barrett AD, Wang T, Weaver SC, Vasconcelos PFC, Rossi SL, Shi PY.

Nat Med. 2017 Jun;23(6):763-767. doi: 10.1038/nm.4322. Epub 2017 Apr 10.

27.

Yellow fever live attenuated vaccine: A very successful live attenuated vaccine but still we have problems controlling the disease.

Barrett ADT.

Vaccine. 2017 Oct 20;35(44):5951-5955. doi: 10.1016/j.vaccine.2017.03.032. Epub 2017 Mar 30. Review.

PMID:
28366605
28.

Live Attenuated Yellow Fever 17D Vaccine: A Legacy Vaccine Still Controlling Outbreaks In Modern Day.

Collins ND, Barrett AD.

Curr Infect Dis Rep. 2017 Mar;19(3):14. doi: 10.1007/s11908-017-0566-9. Review.

29.

MAVS Is Essential for Primary CD4+ T Cell Immunity but Not for Recall T Cell Responses following an Attenuated West Nile Virus Infection.

Luo H, Winkelmann E, Xie G, Fang R, Peng BH, Li L, Lazear HM, Paessler S, Diamond MS, Gale M Jr, Barrett AD, Wang T.

J Virol. 2017 Feb 28;91(6). pii: e02097-16. doi: 10.1128/JVI.02097-16. Print 2017 Mar 15.

30.

Transstadial Transmission and Long-term Association of Crimean-Congo Hemorrhagic Fever Virus in Ticks Shapes Genome Plasticity.

Xia H, Beck AS, Gargili A, Forrester N, Barrett AD, Bente DA.

Sci Rep. 2016 Oct 24;6:35819. doi: 10.1038/srep35819.

31.

Differential Infectivities among Different Japanese Encephalitis Virus Genotypes in Culex quinquefasciatus Mosquitoes.

Huang YS, Hettenbach SM, Park SL, Higgs S, Barrett AD, Hsu WW, Harbin JN, Cohnstaedt LW, Vanlandingham DL.

PLoS Negl Trop Dis. 2016 Oct 5;10(10):e0005038. doi: 10.1371/journal.pntd.0005038. eCollection 2016 Oct.

32.

Fast-Track Zika Vaccine Development - Is It Possible?

Thomas SJ, L'Azou M, Barrett AD, Jackson NA.

N Engl J Med. 2016 Sep 29;375(13):1212-6. doi: 10.1056/NEJMp1609300. No abstract available.

33.

Zika Virus: Diagnosis, Therapeutics, and Vaccine.

Shan C, Xie X, Barrett AD, Garcia-Blanco MA, Tesh RB, Vasconcelos PF, Vasilakis N, Weaver SC, Shi PY.

ACS Infect Dis. 2016 Mar 11;2(3):170-2. doi: 10.1021/acsinfecdis.6b00030. Epub 2016 Mar 3.

PMID:
27623030
34.

Vaccinology in the twenty-first century.

Barrett ADT.

NPJ Vaccines. 2016 Jul 28;1:16009. doi: 10.1038/npjvaccines.2016.9. eCollection 2016. No abstract available.

35.

Research and development of Zika virus vaccines.

Dawes BE, Smalley CA, Tiner BL, Beasley DW, Milligan GN, Reece LM, Hombach J, Barrett AD.

NPJ Vaccines. 2016 Jul 28;1:16007. doi: 10.1038/npjvaccines.2016.7. eCollection 2016.

36.

Yellow Fever in Angola and Beyond--The Problem of Vaccine Supply and Demand.

Barrett AD.

N Engl J Med. 2016 Jul 28;375(4):301-3. doi: 10.1056/NEJMp1606997. Epub 2016 Jun 8. No abstract available.

37.

An Infectious cDNA Clone of Zika Virus to Study Viral Virulence, Mosquito Transmission, and Antiviral Inhibitors.

Shan C, Xie X, Muruato AE, Rossi SL, Roundy CM, Azar SR, Yang Y, Tesh RB, Bourne N, Barrett AD, Vasilakis N, Weaver SC, Shi PY.

Cell Host Microbe. 2016 Jun 8;19(6):891-900. doi: 10.1016/j.chom.2016.05.004. Epub 2016 May 16.

38.

A humanized monoclonal antibody neutralizes yellow fever virus strain 17D-204 in vitro but does not protect a mouse model from disease.

Calvert AE, Dixon KL, Piper J, Bennett SL, Thibodeaux BA, Barrett AD, Roehrig JT, Blair CD.

Antiviral Res. 2016 Jul;131:92-9. doi: 10.1016/j.antiviral.2016.04.013. Epub 2016 Apr 26.

39.

Introduction.

Coller BA, Barrett AD, Thomas SJ.

Vaccine. 2015 Dec 10;33(50):7049-50. doi: 10.1016/j.vaccine.2015.10.087. Epub 2015 Oct 24. No abstract available.

PMID:
26597033
40.

Dysregulation of Toll-Like Receptor 7 Compromises Innate and Adaptive T Cell Responses and Host Resistance to an Attenuated West Nile Virus Infection in Old Mice.

Xie G, Luo H, Pang L, Peng BH, Winkelmann E, McGruder B, Hesse J, Whiteman M, Campbell G, Milligan GN, Cong Y, Barrett AD, Wang T.

J Virol. 2015 Nov 18;90(3):1333-44. doi: 10.1128/JVI.02488-15. Print 2016 Feb 1.

41.

Susceptibility of a North American Culex quinquefasciatus to Japanese Encephalitis Virus.

Huang YJ, Harbin JN, Hettenbach SM, Maki E, Cohnstaedt LW, Barrett AD, Higgs S, Vanlandingham DL.

Vector Borne Zoonotic Dis. 2015 Nov;15(11):709-11. doi: 10.1089/vbz.2015.1821.

PMID:
26565775
42.

Mouse models of dengue virus infection for vaccine testing.

Sarathy VV, Milligan GN, Bourne N, Barrett AD.

Vaccine. 2015 Dec 10;33(50):7051-60. doi: 10.1016/j.vaccine.2015.09.112. Epub 2015 Oct 23. Review.

43.

Defining New Therapeutics Using a More Immunocompetent Mouse Model of Antibody-Enhanced Dengue Virus Infection.

Pinto AK, Brien JD, Lam CY, Johnson S, Chiang C, Hiscott J, Sarathy VV, Barrett AD, Shresta S, Diamond MS.

MBio. 2015 Sep 15;6(5):e01316-15. doi: 10.1128/mBio.01316-15.

44.

Current status and future prospects of yellow fever vaccines.

Beck AS, Barrett AD.

Expert Rev Vaccines. 2015;14(11):1479-92. doi: 10.1586/14760584.2015.1083430. Epub 2015 Sep 14. Review.

45.

Characterization of lethal dengue virus type 4 (DENV-4) TVP-376 infection in mice lacking both IFN-α/β and IFN-γ receptors (AG129) and comparison with the DENV-2 AG129 mouse model.

Sarathy VV, Infante E, Li L, Campbell GA, Wang T, Paessler S, Robert Beatty P, Harris E, Milligan GN, Bourne N, Barrett AD.

J Gen Virol. 2015 Oct;96(10):3035-48. doi: 10.1099/jgv.0.000246. Epub 2015 Jul 14.

46.

A Dengue Virus Type 4 Model of Disseminated Lethal Infection in AG129 Mice.

Milligan GN, Sarathy VV, Infante E, Li L, Campbell GA, Beatty PR, Harris E, Barrett AD, Bourne N.

PLoS One. 2015 May 4;10(5):e0125476. doi: 10.1371/journal.pone.0125476. eCollection 2015.

47.

Tau immunotherapy modulates both pathological tau and upstream amyloid pathology in an Alzheimer's disease mouse model.

Castillo-Carranza DL, Guerrero-Muñoz MJ, Sengupta U, Hernandez C, Barrett AD, Dineley K, Kayed R.

J Neurosci. 2015 Mar 25;35(12):4857-68. doi: 10.1523/JNEUROSCI.4989-14.2015.

48.

A West Nile virus NS4B-P38G mutant strain induces cell intrinsic innate cytokine responses in human monocytic and macrophage cells.

Xie G, Luo H, Tian B, Mann B, Bao X, McBride J, Tesh R, Barrett AD, Wang T.

Vaccine. 2015 Feb 11;33(7):869-78. doi: 10.1016/j.vaccine.2014.12.056. Epub 2015 Jan 3.

49.

In vitro analysis of MyD88-mediated cellular immune response to West Nile virus mutant strain infection.

Xie G, Whiteman MC, Wicker JA, Barrett AD, Wang T.

J Vis Exp. 2014 Nov 27;(93):e52121. doi: 10.3791/52121.

50.

Attenuated West Nile virus mutant NS1130-132QQA/175A/207A exhibits virus-induced ultrastructural changes and accumulation of protein in the endoplasmic reticulum.

Whiteman MC, Popov V, Sherman MB, Wen J, Barrett AD.

J Virol. 2015 Jan 15;89(2):1474-8. doi: 10.1128/JVI.02215-14. Epub 2014 Nov 12.

Supplemental Content

Loading ...
Support Center